Max S. Wicha

Point: cancer stem cells--the evidence accumulates.

Prospective identification of tumorigenic breast cancer cells.

In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

Stem cells in normal breast development and breast cancer.

Breast cancer, stem/progenitor cells and the estrogen receptor.

New organizational and funds flow models for an academic cancer center.

Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells.

Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia.

Mammary stem cells, self-renewal pathways, and carcinogenesis.

Cancer stem cells: an old idea--a paradigm shift.

Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells.

Identification of murine mammary stem cells: implications for studies of mammary development and carcinogenesis.

Cancer stem cells and metastasis: lethal seeds.

Stem cells in mammary development and carcinogenesis: implications for prevention and treatment.

Mammary stem cell number as a determinate of breast cancer risk.

Breast cancer stem cells: the other side of the story.

Breast cancer stem cells-research opportunities utilizing mathematical modeling.

Selective targeting of cancer stem cells: a new concept in cancer therapeutics.

Cancer stem cells: implications for cancer treatment and prevention.

[The cancer stem cell: the breast cancer driver].

BRCA1 regulates human mammary stem/progenitor cell fate.

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Cancer stem cell heterogeneity in hereditary breast cancer.

Cancer stem cells: a step toward the cure.

Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.

Cancer stem cells in breast: current opinion and future challenges.

Colon cancer stem cells: implications for prevention and therapy.

[Stem cells and epithelial cancers: the example of breast cancer].

Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.

Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.

Tumor-initiating cells and treatment resistance: how goes the war?

HER-2, notch, and breast cancer stem cells: targeting an axis of evil.

Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.

Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.

Getting to the root of BRCA1-deficient breast cancer.

Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer.

Retinoid signaling regulates breast cancer stem cell differentiation.

An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma.

Targeting breast stem cells with the cancer preventive compounds curcumin and piperine.

Identification of single chain antibodies to breast cancer stem cells using phage display.

Targeting breast cancer stem cells.

Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.

Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase.

Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells.

Cancer stem cells: nature versus nurture.

Targeting breast cancer stem cells.

Breast tumors: of mice and women.

Targeting breast cancer stem cells.

Stem cells in normal development and cancer.

Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells.

Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks.

Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds.

Stemming a tumor with a little miR.

Circulating tumor cells: not all detected cells are bad and not all bad cells are detected.

Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.

Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.

Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots.

Ablation of breast cancer stem cells with radiation.

Inflammation and autophagy conspire to promote tumor growth.

Breast cancer stem cells, cytokine networks, and the tumor microenvironment.

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.

Role of microRNAs in the regulation of breast cancer stem cells.

Antiangiogenic agents: fueling cancer's hypoxic roots.

Cancer stem cell vaccination confers significant antitumor immunity.

PSA lo and behold: prostate cancer stem cells.

MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells.

Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer.

HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.

Migratory gene expression signature predicts poor patient outcome: Are cancer stem cells to blame?

Targeting cancer stem cells via dendritic-cell vaccination.

Breast cancer stem cells: we've got them surrounded.

Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.

B4 androgen ablation: attacking the prostate cancer stem cell.

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma.

HER2 and breast cancer stem cells: more than meets the eye.

Distinct FAK activities determine progenitor and mammary stem cell characteristics.

Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.

The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype.

Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets.

Clinical trial design for testing the stem cell model for the prevention and treatment of cancer.

Evaluation of STAT3 Signaling in ALDH+ and ALDH+/CD44+/CD24- Subpopulations of Breast Cancer Cells.